Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...

A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity. Rising ...

Does compounded Semaglutide work for weight loss? Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But it’s important to understand ...

According to Novo Nordisk, this study was the first to compare these GLP-1 receptor agonists in a real-world setting. Findings from a real-world study evaluating cardiovascular disease-related ...

Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. In a ...

A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with obesity, including those with type 2 diabetes (T2D), according to ...

Please provide your email address to receive an email when new articles are posted on . In a real-world cohort of patients with obesity and heart disease but not diabetes, semaglutide prevented more ...

Compared with tirzepatide, semaglutide reduced the risk of MI, stroke, or death from any cause by 57% in patients with overweight/obesity and CVD. The real-world STEER trial was a retrospective, ...

Semaglutide showed no significant association with increased risk of eye disorders or diabetic retinopathy in the meta-analysis. A potential link between semaglutide and increased risk of NAION was ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the agency announced. The glucagon-like peptide-1 ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

June 27 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign ...